NEW YORK (GenomeWeb News) – Bioinformatics firm Genome Compiler has raised $500,000 toward a targeted round of $5 million, the company said in a document filed with the US Securities and Exchange Commission this week.

The Northern California-based firm did not identify investors in the round or say how the proceeds will be used. In its Form D filed with the SEC, it said that the type of securities offered comprised equity and security to be acquired upon exercise of option, warrant, or other right to acquire security.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.